Pierre-Paul Axisa
Overview
Explore the profile of Pierre-Paul Axisa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wei J, Moon J, Yasumizu Y, Zhang L, Raddassi K, Buitrago-Pocasangre N, et al.
J Clin Invest
. 2025 Mar;
PMID: 40067358
Multiple sclerosis (MS) is a complex genetically mediated autoimmune disease of the central nervous system where anti-CD20-mediated B cell depletion is remarkably effective in the treatment of early disease. While...
2.
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, et al.
Nat Immunol
. 2024 Nov;
26(1):82-91.
PMID: 39609626
Effective anti-tumor immunity is driven by cytotoxic CD8 T cells with specificity for tumor antigens. However, the factors that control successful tumor rejection are not well understood. Here we identify...
3.
Hutchison W, Keyes T, Crowell H, Serizay J, Soneson C, Davis E, et al.
Nat Methods
. 2024 Jun;
21(7):1166-1170.
PMID: 38877315
The growth of omic data presents evolving challenges in data manipulation, analysis and integration. Addressing these challenges, Bioconductor provides an extensive community-driven biological data analysis platform. Meanwhile, tidy R programming...
4.
Blanquart E, Ekren R, Rigaud B, Joubert M, Baylot V, Daunes H, et al.
Blood
. 2024 Jun;
144(12):1271-1283.
PMID: 38875515
The promising results obtained with immunotherapeutic approaches for multiple myeloma (MM) call for a better stratification of patients based on immune components. The most pressing being cytotoxic lymphocytes such as...
5.
Hutchison W, Keyes T, Crowell H, Serizay J, Soneson C, Davis E, et al.
bioRxiv
. 2024 Jun;
PMID: 38826347
The growth of omic data presents evolving challenges in data manipulation, analysis, and integration. Addressing these challenges, Bioconductor provides an extensive community-driven biological data analysis platform. Meanwhile, tidy R programming...
6.
Lincoln M, Connally N, Axisa P, Gasperi C, Mitrovic M, van Heel D, et al.
Nat Genet
. 2024 May;
56(5):838-845.
PMID: 38741015
Autoimmune and inflammatory diseases are polygenic disorders of the immune system. Many genomic loci harbor risk alleles for several diseases, but the limited resolution of genetic mapping prevents determining whether...
7.
Hafler D, Lu B, Lucca L, Lewis W, Wang J, Nogeuira C, et al.
Res Sq
. 2024 Mar;
PMID: 38464315
Effective anti-tumor immunity is largely driven by cytotoxic CD8 T cells that can specifically recognize tumor antigens. However, the factors which ultimately dictate successful tumor rejection remain poorly understood. Here...
8.
Wei J, Moon J, Yasumizu Y, Zhang L, Radassi K, Buitrago-Pocasangre N, et al.
bioRxiv
. 2024 Feb;
PMID: 38370778
Multiple sclerosis (MS) is a complex genetically mediated autoimmune disease of the central nervous system where anti-CD20-mediated B cell depletion is remarkably effective in the treatment of early disease. While...
9.
Pichler A, Carrie N, Cuisinier M, Ghazali S, Voisin A, Axisa P, et al.
Immunity
. 2023 Jul;
56(7):1631-1648.e10.
PMID: 37392737
CD137 (4-1BB)-activating receptor represents a promising cancer immunotherapeutic target. Yet, the cellular program driven by CD137 and its role in cancer immune surveillance remain unresolved. Using T cell-specific deletion and...
10.
Axisa P, Yoshida T, Lucca L, Kasler H, Lincoln M, Pham G, et al.
Sci Transl Med
. 2022 Dec;
14(675):eabl3651.
PMID: 36516268
Genome-wide association studies identifying hundreds of susceptibility loci for autoimmune diseases indicate that genes active in immune cells predominantly mediate risk. However, identification and functional characterization of causal variants remain...